Aileron Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

James Windsor

İcra Kurulu Başkanı

US$715.9k

Toplam tazminat

CEO maaş yüzdesi	11.9%
CEO görev süresi	1.1yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	6.2yrs

Son yönetim güncellemeleri

Recent updates

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aug 18

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Dec 30

CEO Tazminat Analizi

James Windsor'un ücretlendirmesi Aileron Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$18m
Dec 31 2023	US$716k	US$85k	-US$16m

Tazminat ve Piyasa: James 'ın toplam tazminatı ($USD 715.92K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 653.78K ).

Tazminat ve Kazançlar: James şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

James Windsor (58 yo)

1.1yrs

Görev süresi

US$715,921

Tazminat

Dr. James Brian Windsor, Ph.D. is Chief Executive Officer and Director of Aileron Therapeutics, Inc. from March 11, 2024 and its President. Dr. Windsor served as Chief Operating Officer and President from...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Windsor	CEO, President & Director	less than a year	US$715.92k	0.033% $ 28.5k
Josef von Rickenbach	Independent Chairman	5.4yrs	US$67.97k	0.10% $ 89.1k
Alan Musso	Independent Director	1.1yrs	US$15.64k	0% $ 0
Carol Prives	Member of Scientific Advisory Board	6.7yrs	Veri yok	Veri yok
Brian Druker	Member of Scientific Advisory Board	6.7yrs	Veri yok	Veri yok
Alan List	Member of Scientific Advisory Board	6.7yrs	Veri yok	Veri yok
Reinhard Ambros	Independent Lead Director	11.4yrs	US$46.25k	0.0013% $ 1.2k
William Fairey	Independent Director	1.1yrs	US$9.38k	0% $ 0
Manuel Aivado	Director	6.2yrs	US$630.74k	0.00023% $ 199.3
Ulrich Steidl	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

6.2yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALRN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.2 yıldır).

Aileron Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

New major risk - Share price stability

New minor risk - Share price stability

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 44% to US$13.00

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Aileron Therapeutics, Inc. announced delayed annual 10-K filing

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Aileron Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Share price stability

New minor risk - Shareholder dilution

Aileron Therapeutics, Inc. (NasdaqCM:ALRN) acquired Lung Therapeutics, Inc.

Aileron Therapeutics, Inc. announced that it expects to receive $16.4 million in funding from Nantahala Capital Management, LLC and other investors

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

Insufficient new directors

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aileron Therapeutics Outlines Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Insufficient new directors

Insufficient new directors

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN 6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Aileron Therapeutics Appoints Susan L. Drexler as Interim Chief Financial Officer

Aileron Therapeutics, Inc. Appoints Manuel Aivado as Principal Financial Officer and Principal Accounting Officer

Aileron Therapeutics Announces First Patients Treated in Phase 1B Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron Therapeutics, Inc. Announces Resignation of Richard J. Wanstall as Chief Financial Officer, Effective from May 6, 2022

Price target decreased to US$2.00

Less than half of directors are independent

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$2.00

Less than half of directors are independent

Aileron Therapeutics: An Assessment On A Lottery Ticket

Aileron Therapeutics, Inc. Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics: Solving Chemotherapy's Toxicity

Aileron Therapeutics, Inc. Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $35.894081 million.

Aileron Therapeutics +31% on insider buying more shares

Aileron raises $40M via equity offering

Aileron Therapeutics EPS in-line

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.762 million.

Aileron Therapeutics, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Aileron Therapeutics, Inc.(NasdaqCM:ALRN) dropped from Russell Microcap Value Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş